Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results

Pulmatrix Inc PULM announced topline results of its recently completed Phase 1b clinical study of PUR1800 in patients with stable Chronic Obstructive Pulmonary Disease (COPD).
PUR1800 is a narrow spectrum kinase inhibitor (NSKI) administered as a dry powder for inhalation with iSPERSE.
Initial safety and pharmacokinetics (PK) were evaluated in patients with stable COPD.
The Phase 1b trial was designed as a randomized, double-blind, placebo-controlled, 3-way crossover study to assess the safety, tolerability, and PK of repeated once-daily doses of PUR1800 or placebo for 14 days, in adult patients with stable COPD.
A total of 18 subjects were enrolled. Safety and tolerability, as well as systemic PK, were evaluated.
PUR1800 was well-tolerated, and there were no observed safety signals. The preliminary PK data indicate that PUR1800 results in low and consistent systemic exposure when administered via oral inhalation.
Price Action: PULM shares are down 5.92% at $6.35 during the market session on the last check Monday.